Background-C-reactive protein (CRP) is a heritable marker of chronic inflammation that is strongly associated with cardiovascular disease. We sought to identify genetic variants that are associated with CRP levels. Methods and Results-We performed a genome-wide association analysis of CRP in 66 185 participants from 15 population-based studies. We sought replication for the genome-wide significant and suggestive loci in a replication
panel comprising 16 540 individuals from 10 independent studies. We found 18 genome-wide significant loci, and we provided evidence of replication for 8 of them. Our results confirm 7 previously known loci and introduce 11 novel loci that are implicated in pathways related to the metabolic syndrome (APOC1, HNF1A, LEPR, GCKR, HNF4A, and PTPN2) or the immune system (CRP, IL6R, NLRP3, IL1F10, and IRF1) or that reside in regions previously not known to play a role in chronic inflammation (PPP1R3B, SALL1, PABPC4, ASCL1, RORA, and BCL7B). We found a significant interaction of body mass index with LEPR (PϽ2.9ϫ10 Ϫ6 ). A weighted genetic risk score that was developed to summarize the effect of risk alleles was strongly associated with CRP levels and explained Ϸ5% of the trait variance; however, there was no evidence for these genetic variants explaining the association of CRP with coronary heart disease. Conclusions-We identified 18 loci that were associated with CRP levels. Our study highlights immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation. (Circulation. 2011;123:731-738.)
Key Words: genetics Ⅲ inflammation Ⅲ meta-analysis Ⅲ myocardial infarction Ⅲ genome-wide association study C -reactive protein (CRP) is a general marker of systemic inflammation. High CRP levels are associated with increased risks of mortality 1 and major diseases including diabetes mellitus, 2 hypertension, 3 coronary heart disease (CHD), 4 and stroke. 5 The heritability of CRP levels is estimated to be 25% to 40%, 6 -8 suggesting that genetic variation is a major determinant of CRP levels. A genome-wide association (GWA) study in 6345 women found 7 loci associated with CRP levels. 9 These loci were in or close to genes encoding CRP (CRP), leptin receptor (LEPR), interleukin-6 receptor (IL6R), glucokinase regulator (GCKR), hepatic nuclear factor 1-␣ (HNF1A), apolipoprotein E (APOE), and achaete-scute complex homolog 1 (ASCL1). Findings from other GWA studies did not extend the number of loci related to CRP. 10, 11 Clinical Perspective on p 738
In this study, we sought to discover additional genes related to CRP levels using GWA scans in 66 185 participants from 15 population-based cohort studies and replicate our findings in 16 540 participants from 10 independent studies. To investigate whether the genetic variants identified interact with nongenetic determinants of CRP such as age, sex, smoking, and body mass index (BMI), we examined gene-environment interactions. Finally, the extent to which the genes associated with circulating CRP levels, individually or jointly, affect the risk of cardiovascular diseases is still unknown. To address this question, we examined the association of genetic variants with myocardial infarction (MI) and CHD.
Methods

Subjects and Measurements
Participants were of European ancestry. All studies had protocols approved by local institutional review boards. Participants provided written informed consent and gave permission to use their DNA for research purposes. Baseline characteristics for all participating studies are presented in Table I 
GWA Analysis
Genome-wide scans were performed independently in each cohort with the use of various genotyping technologies (Table VII in the online-only Data Supplement). Investigators in each study performed association analysis using the genotype-phenotype data within their cohort. Each study imputed single-nucleotide polymorphisms (SNPs) with reference to HapMap release 22 CEU and provided results for a common set of SNPs for meta-analysis. Except for the FHS, all studies conducted a linear regression analysis adjusted for age (except for NFBC66 and B58C), sex (except for the Women's Genome Health Study [WGHS] ), and site of recruitment (if necessary) for all SNPs based on an additive genetic model. In the Erasmus Rucphen Family (ERF) study, adjustments for the family structure in the GWA analysis were based on the model residuals in the score test, which accounted for pedigree structure as implemented in GenABEL software 12 function "mmscore." 13 In the FHS, a linear mixed effects model was employed with the use of the lmekin function of the kinship package in R with a fixed additive effect for the SNP genotype, fixed covariate effects, and random familyspecific additive residual polygenic effects. 14 In each study, we estimated the genomic inflation rate, stated as lambda (gc), by comparing each study's median 2 value to 0.4549, the median 2 for the null distribution 15 (Table I in the online-only Data Supplement). P values for each cohort were adjusted for underlying population structure with the genomic inflation coefficient.
Discovery Panel and Replication Panel
The 15-study discovery panel included 5 studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, 16 4 studies from the European Special Population Network (EUROSPAN), and 6 additional independent studies comprising 66 185 participants. The replication studies included 10 independent studies and 16 540 participants.
Meta-Analysis
To calculate the combined P values and ␤ coefficients, we used an inverse-variance weighted fixed-effects meta-analysis. We used METAL, a software package designed to perform meta-analysis on GWA data sets. 17 We applied an a priori threshold 5.0ϫ10
Ϫ8 for genome-wide significance. 18 When Ͼ1 genome-wide significant SNP clustered at a locus, we took the SNP with the smallest P value as the lead SNP. To investigate the validity of our findings, we sought replication of the lead SNP in genome-wide significant (PϽ5ϫ10 ) in our replication panel. We ran a fixed-effect meta-analysis to combine the results of the discovery and replication panels. The first GWA study on serum CRP published by Ridker et al 9 was based on part of the WGHS population. To confirm that our findings were not entirely influenced by these previously published results, we performed a meta-analysis excluding the WGHS population.
Examination of Heterogeneity
We examined between-study heterogeneity with Cochran's Q test. On the basis of Bonferroni adjustment for 18 tests, heterogeneity was considered significant at a P value Ͻ2.8ϫ10 Ϫ3 . We explored the source of heterogeneity for significant SNPs by fitting a covariate (age, gender, BMI, or smoking) in a meta-regression model.
Gene-Environment Interaction
For all genome-wide significant SNPs, we examined gene-by-age, gene-by-sex, gene-by-BMI, and gene-by-smoking interactions in each study by introducing an interaction term into a linear model with age, sex, and the covariate of interest as the independent variables and natural log-transformed CRP as the outcome. A meta-analysis was performed to combine the reported interaction ␤ and P values across studies for each of the top SNPs. On the basis of Bonferroni adjustment for 72 tests (18 SNPs for 4 environmental factors), we used a significance threshold at 6.9ϫ10. 
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*␤ coefficient represents 1-unit change in the natural log-transformed CRP (mg/L) per copy increment in the coded allele. 
Genetic Risk Score
To model the cumulative effect of the identified loci, we created a genetic risk score comprising information from the genome-wide significant SNPs. The risk score was computed for each subject by multiplying the number of alleles associated with higher CRP by the ␤ coefficient from the combined meta-analysis and taking the sum over the SNPs. To make the genetic risk score easier to interpret, we rescaled to range from zero (low CRP level) to 100 (high CRP level).
Association With MI and CHD
The association of the genome-wide significant SNPs and the genetic risk score with clinical events was tested in the ARIC study, the Age, Gene/Environment Susceptibility-Reykjavik (AGES) study, the Cardiovascular Health Study (CHS), the FHS, the Rotterdam Study (RS), and the WGHS with the use of incident cases of MI and CHD (ie, occurring after CRP concentrations were measured). Incident MI included fatal and nonfatal MI. Incident CHD included incident fatal and nonfatal MI, fatal CHD, and sudden death. Each study examined the associations with the use of a Cox proportional hazards model adjusted for age and sex. We subsequently combined these results by performing a meta-analysis.
Results
The basic characteristics of the participating studies are shown in Table I in the online-only Data Supplement. Figure I ) in the replication stage. In a fixed-effects metaanalysis of the discovery and replication panels, 18 loci showed a genome-wide significant association: 15 loci of the 17 genome-wide significant loci (Table 2 ) and 3 loci of the 47 suggestive loci (Table 3 ). In addition to confirming 7 previously reported associations, the genome-wide significant signals marked 11 novel associations within or close to the NLR family, pyrin domain containing 3 (NLRP3), interleukin-1 family, member 10 (IL1F10), protein phosphatase 1, regulatory (inhibitor) subunit 3B (PPP1R3B), hepatocyte nuclear factor 4-␣ (HNF4A), RAR-related orphan receptor A (RORA), Sal-like 1 (SALL1), poly(A) binding protein, cytoplasmic 4 (inducible form) (PABPC4), B-cell chronic lymphocytic leukemia/lymphoma 7B (BCL7B), proteasome assembly chaperone 1 (PSMG1), protein tyrosine phosphatase, nonreceptor type 2 (PTPN2), G proteincoupled receptor, family C, group 6, member A (GPRC6A), and interferon regulatory factor 1 (IRF1). Furthermore, our metaanalysis excluding the WGHS population (Table III in the online-only Data Supplement) confirmed the association of 7 previously known genes, 9 CRP, APOE (APOC1), HNF1A, LEPR, IL6R, GCKR, and ASCL1, with CRP levels (Bonferroni significance level: 0.05/7ϭ7.1ϫ10
Ϫ3
). Figure 1 presents the average CRP levels across the genetic risk score in the whole population. Individuals in the highest gene score group had a mean CRP level (4.12 mg/L; 95% confidence interval, 4.96 to 5.25) that was more than double the level observed for individuals in the lowest gene score group (1.40 mg/L; 95% confidence interval, 1.31 to 1.49). The percentage of overall variance in CRP that was explained by the genetic risk score ranged from 1.2% to 10.3% across studies in the discovery and replication panels and was more than 5% in half of the studies.
After adjustment for number of tests, significant heterogeneity was found for rs2794520, rs4420065, rs4129267, rs1260326, and rs10745954 (Tables 2 and 3 ). Meta-regression was used to explore the source of heterogeneity. Sex was associated with heterogeneity for rs10745954 (PϽ2.8ϫ10 Ϫ5 ) (Table VI in the online-only Data Supplement).
All 18 SNPs that showed genome-wide significant results in the combined meta-analyses were studied for interactions with age, sex, BMI, and smoking (Table IV in the online-only Data Supplement). After adjustment for the number of tests, we found a significant interaction between BMI and the LEPR SNP rs4420065 (PϽ2.9ϫ10 Ϫ6 ). We examined the association of the SNPs related to CRP with risk of MI and CHD. These studies comprised 1845 cases of MI and 2947 cases of CHD. Neither the individual SNPs nor the combined genetic risk score showed consistent or genome-wide significant associations with risk of clinical events (Figure 2 ).
Discussion
Through a meta-analysis of GWA scans from 15 cohort studies comprising 66 185 subjects and a replication sample of 16 540 subjects, we identified 18 loci associated with circulating CRP levels and provided evidence of replication for 8 of them. Our results confirm 7 gene-annotated loci reported by Ridker et al. 9 Furthermore, we introduce 11 novel loci associated with CRP levels, annotating NLRP3, IL1F10, PPP1R3B, HNF4A, RORA, SALL1, PAPBC4, BCL7B, PTPN2, GPRC6A, and IRF1.
A number of these genes including APOC1, HNF1A, LEPR, GCKR, HNF4A, and PTPN2 are directly or indirectly related to metabolic regulatory pathways involved in diabetes mellitus. Mutations in HNF1A are associated with impaired insulin secretion and maturity-onset diabetes mellitus of the young (MODY) type 3. 19 HNF4A is part of a complex regulatory network in the liver and pancreas for glucose homeostasis. 20 Mutations in the HNF4A gene cause MODY type 1. 21 HNF4A is a transcription factor involved in the expression of several liver-specific genes including HNF1A. 21 Defects in the expression of GCKR result in deficient insulin secretion. 22 PTPN2, which modulates interferon gamma signal transduction at the ␤ cell level, 23 was recently identified as a novel susceptibility gene for type 1 diabetes mellitus. 24 PTPN2 also is linked to the inflammatory pathway. The nuclear isoform of PTPN2 is a regulator of transcription factor STAT3 in the downstream of interleukin-6 signaling and may affect CRP expression in Hep3B cells. 25 CRP, IL6R, NLRP3, ILF10, and IRF1 are associated with CRP levels at least partly through pathways related to innate and adapted immune response. NLRP3 encodes a member of the NALP3 inflammasome complex. 26 The NALP3 inflammasome triggers an innate immune response and can be activated by endogenous "danger signals," as well as compounds associated with pathogens. 27, 28 Activated NALP3 inflammasome functions as an activator of nuclear factor-B signaling. Nuclear factor-B is a transcription factor that affects CRP expression in Hep3B cells. 29 Our genetic risk score explained Ϸ5% of the variation in CRP levels, showing that genetic factors are of importance in determining CRP levels. In comparison, BMI as the main nongenetic determinant of CRP was reported to explain 5% to 7% of the variation in CRP levels in AGES 30 and up to 15% in FHS. 31 Ridker et al reported that 7 SNPs discovered in their study explained 10.1% of the variation in CRP levels after adjustment for age, smoking, BMI, hormone therapy, and menopausal status. 9 However, without adjustment for these covariates, Ͻ5% of the variation in CRP levels was explained (D. Chasman, PhD, personal written communication, May 2009).
Adipose tissue can induce chronic low-grade inflammation by producing proinflammatory cytokines such as interleukin-6. 32 Therefore, we examined whether adiposity modifies the effect of any of the 18 genes on CRP. We found that BMI modifies the strength of the association between LEPR and CRP. This interaction was initially found in WGHS. 33 There is ample evidence that chronic inflammation is involved in atherosclerosis and cardiovascular disease. In this study, we found no association between genetically elevated CRP and risk of CHD. In agreement with our results, Elliott et al 10 reported in a recent study that variations in the CRP gene are not associated with risk of MI and CHD, but they found associations of LEPR, IL6R, and APOCE-CI-CII with CHD. However, the lack of association with clinical events in our study could also be due to lack of power.
Our study has the benefit of a large and homogeneous sample size of 82 725 subjects of European ancestry. This enabled us to find novel genes with small effect on CRP level. Furthermore, this large sample size enabled us to study gene-environment interaction, which hitherto has been less feasible. In contrast to most other studies, we used only incident cases of cardiovascular events from well-defined population-based studies to examine the relation between the identified SNPs and clinical disease. The study has several limitations. Although we identified 18 loci associated with CRP levels, other genetic loci associated with CRP concentrations may still be missed by our study. Six of the genome-wide significant loci from the discovery panel were significant after Bonferroni correction in the replication panel. The other identified loci need replication for confirmation in larger samples. We acknowledge that our genetic risk score is based on our own findings and may be less efficient when used in another population. Finally, we did not fine map the identified loci; we therefore acknowledge that the identified SNPs may be in linkage disequilibrium with non-HapMap variants causally related to CRP levels.
In conclusion, we identified 11 novel loci and confirmed 7 known loci to affect CRP levels. The results highlight immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation, as well as several loci previously unknown to be related to inflammation. Furthermore, LEPR was found to affect CRP differently in the presence of low or high BMI, which may lead to new insights in the mechanisms underlying inflammation.
